MCID: PRL017
MIFTS: 47

Prolymphocytic Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Prolymphocytic Leukemia

MalaCards integrated aliases for Prolymphocytic Leukemia:

Name: Prolymphocytic Leukemia 12 73 15 70
Leukemia, Prolymphocytic 44
Leukemia Prolymphocytic 54

Classifications:



External Ids:

Disease Ontology 12 DOID:1039
MeSH 44 D015463
NCIt 50 C3181
SNOMED-CT 67 110006004
UMLS 70 C0023486

Summaries for Prolymphocytic Leukemia

MalaCards based summary : Prolymphocytic Leukemia, also known as leukemia, prolymphocytic, is related to b cell prolymphocytic leukemia and t-cell prolymphocytic leukemia. An important gene associated with Prolymphocytic Leukemia is MTCP1 (Mature T Cell Proliferation 1), and among its related pathways/superpathways are IL-2 Pathway and Endometrial cancer. The drugs Ofloxacin and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are Reduced mammosphere formation and Decreased human cytomegalovirus (HCMV) strain AD169 replication

Wikipedia : 73 Prolymphocytic leukemia is divided into two types according to the kind of cell involved: B-cell... more...

Related Diseases for Prolymphocytic Leukemia

Diseases related to Prolymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 257)
# Related Disease Score Top Affiliating Genes
1 b cell prolymphocytic leukemia 32.0 ZAP70 TP53 MYC FCER2 CD5 CD38
2 t-cell prolymphocytic leukemia 31.6 TCL1A MYC MTCP1 JAK3 JAK1 HLA-S
3 t-cell lymphoblastic leukemia/lymphoma 30.5 ZAP70 TCL1A MYC MTCP1 CD7 CCND1
4 anemia, autoimmune hemolytic 30.5 ZAP70 CD52 CD5 CD19
5 adult t-cell leukemia 30.4 TP53 MYC JAK3 CD7
6 ataxia-telangiectasia 30.3 TP53 TCL1A MTCP1 ATM ABL1
7 adult lymphoma 30.2 MYC CD5 CD19
8 pancytopenia 30.2 TP53 CD7 CD5 CD19
9 hairy cell leukemia 30.1 TP53 CD52 CD5 CD38 CCND1 ADA
10 plasma cell leukemia 30.0 MYC CD38 CCND1
11 rare tumor 30.0 FCER2 CR2
12 leukemia 29.9 TP53 TCL1A MYC MTCP1 JAK3 JAK1
13 lymphoblastic lymphoma 29.9 TP53 MYC CD7 CD5
14 leukemia, chronic lymphocytic 2 29.9 ZAP70 FCER2 CD5 CD38 ATM
15 plasmacytoma 29.9 MYC CD5 CD38 CCND1
16 precursor t-cell acute lymphoblastic leukemia 29.9 TCL1A MYC CD7 ABL1
17 diffuse large b-cell lymphoma 29.8 TP53 MYC CD5 CD38 CD19 CCND1
18 t-cell adult acute lymphocytic leukemia 29.7 TP53 JAK3 CD7 CD52 CD5
19 richter's syndrome 29.7 ZAP70 TP53 MYC CD5 CD38 CD19
20 sezary's disease 29.5 TP53 MYC JAK3 CD7 CD52 CD5
21 mantle cell lymphoma 29.5 TP53 TCL1A MYC CD52 CD5 CD19
22 burkitt lymphoma 29.4 TP53 TCL1A MYC FCER2 CR2 CD19
23 peripheral t-cell lymphoma 29.3 TP53 TCL1A JAK3 CD5 CD38 CD19
24 lymphoma 29.3 TP53 TCL1A MYC CR2 CD5 CD38
25 cll/sll 29.2 ZAP70 TP53 CD5 CD38 CD19 CCND1
26 myeloma, multiple 29.2 TP53 MYC CD5 CD38 CD19 CCND1
27 t-cell acute lymphoblastic leukemia 29.1 TP53 MYC JAK3 JAK1 CD38 ATM
28 b-cell lymphoma 29.0 ZAP70 TP53 TCL1A MYC FCER2 CR2
29 lymphoma, mucosa-associated lymphoid type 29.0 ZAP70 TP53 MYC CR2 CD5 CD19
30 leukemia, acute lymphoblastic 28.5 ZAP70 TP53 TCL1A MYC JAK3 JAK1
31 leukemia, chronic lymphocytic 28.3 ZAP70 TP53 TCL1A MYC FCER2 CR2
32 leukemia, acute myeloid 28.2 TP53 MYC JAK3 JAK1 CD7 CD5
33 lymphoma, non-hodgkin, familial 27.9 TP53 TCL1A MYC FCER2 CR2 CD7
34 splenic manifestation of prolymphocytic leukemia 11.1
35 splenomegaly 10.8
36 leukemia, t-cell, chronic 10.7
37 lymphoproliferative syndrome 10.6
38 chromosomal triplication 10.6
39 lymphoma aids related 10.4 TCL1A MYC
40 endocrine exophthalmos 10.4 CD5 ATM
41 appendix lymphoma 10.4 MYC CD5
42 telangiectasis 10.4
43 intravascular large b-cell lymphoma 10.3 MYC CD5
44 parapsoriasis 10.3 CD7 CD5
45 listeria meningitis 10.3 CD52 ADA
46 immunodeficiency 19 10.3 ZAP70 ADA
47 anal carcinoma in situ 10.3 TP53 MYC
48 ataxia and polyneuropathy, adult-onset 10.3
49 graft-versus-host disease 10.3
50 refractory hematologic cancer 10.3 CD38 CD19

Graphical network of the top 20 diseases related to Prolymphocytic Leukemia:



Diseases related to Prolymphocytic Leukemia

Symptoms & Phenotypes for Prolymphocytic Leukemia

GenomeRNAi Phenotypes related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 ATM CCND1 CD5 CD52 CD7 JAK3
2 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.13 ATM JAK3 ZAP70

MGI Mouse Phenotypes related to Prolymphocytic Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.15 ABCB4 ABL1 ADA ATM CCND1 CD19
2 hematopoietic system MP:0005397 10.06 ABCB4 ABL1 ADA ATM CCND1 CD19
3 endocrine/exocrine gland MP:0005379 10.03 ABCB4 ABL1 ADA ATM CCND1 CD38
4 digestive/alimentary MP:0005381 9.97 ABCB4 ABL1 ADA CCND1 CD19 FCER2
5 immune system MP:0005387 9.86 ABCB4 ABL1 ADA ATM CCND1 CD19
6 normal MP:0002873 9.28 ABL1 ADA CCND1 CD19 CD5 JAK1

Drugs & Therapeutics for Prolymphocytic Leukemia

Drugs for Prolymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 243)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ofloxacin Approved Phase 3 82419-36-1 4583
2
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
3
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
4
Dalteparin Approved Phase 3 9005-49-6
5
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
6
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
7
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
8
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
9
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
10
Iron Approved Phase 3 7439-89-6 23925 29936
11
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
12
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
14
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
15 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
16 Neurotransmitter Agents Phase 3
17 Anesthetics, Dissociative Phase 3
18 Analgesics Phase 3
19 Cola Phase 3
20 Heparin, Low-Molecular-Weight Phase 3
21 Narcotics Phase 3
22 Excitatory Amino Acid Antagonists Phase 3
23 Analgesics, Opioid Phase 3
24 Epoetin alfa Phase 3 113427-24-0
25 Hematinics Phase 3
26 Antiparasitic Agents Phase 3
27 Antiprotozoal Agents Phase 3
28 Liver Extracts Phase 3
29 Amebicides Phase 3
30 Liposomal amphotericin B Phase 3
31 Anesthetics Phase 3
32 Anesthetics, Intravenous Phase 3
33 Anesthetics, General Phase 3
34 ferric gluconate Phase 3
35 Iron Supplement Phase 3
36
Mitoxantrone Approved, Investigational Phase 2 65271-80-9 4212
37
Cytarabine Approved, Investigational Phase 1, Phase 2 147-94-4 6253
38
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
39
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
40
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
41
Mesna Approved, Investigational Phase 2 3375-50-6 598
42
Adenosine Approved, Investigational Phase 2 58-61-7 60961
43
Pentostatin Approved, Investigational Phase 2 53910-25-1 439693 40926
44
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
45
Carmustine Approved, Investigational Phase 2 154-93-8 2578
46
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
47
Vidarabine Approved, Investigational Phase 1, Phase 2 24356-66-9 21704 32326
48
ofatumumab Approved Phase 1, Phase 2 679818-59-8 6918251
49
Auranofin Approved, Investigational Phase 2 34031-32-8 6918453 6333901
50
Atorvastatin Approved Phase 2 134523-00-5 60823

Interventional clinical trials:

(show top 50) (show all 189)
# Name Status NCT ID Phase Drugs
1 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
2 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
3 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
4 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
5 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
6 Daily Versus Weekly Administration of 2-Chlorodeoxyadenosine (CDA) in Patients With Hairy Cell Leukemia Completed NCT00003746 Phase 3 2-chlorodeoxyadenosine (CDA) daily;2-chlorodeoxyadenosine weekly
7 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
8 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
9 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
10 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
11 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
12 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
13 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
14 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
15 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
16 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
17 Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02819583 Phase 1, Phase 2
18 Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02851589 Phase 1, Phase 2
19 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
20 PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02892695 Phase 1, Phase 2
21 Clinical Study of CD19/CD22 Tan CAR T Cells in Relapsed and/or Chemotherapy Refractory B-cell Leukemias and Lymphomas Unknown status NCT03185494 Phase 1, Phase 2
22 Pilot Study of Redirected Autologous T Cells Transduced to Express A CD20-Specific Chimeric Immunoreceptor in Patient With Chemotherapy Resistant or Refractory CD20+ Leukemia and Lymphoma Unknown status NCT01735604 Phase 1, Phase 2
23 Minimal Ablation and Cellular Immune Therapy of Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Low-Grade Non-Hodgkin's Lymphoma, and Mantle Cell Lymphoma With Allogeneic Donor Stem Cells Completed NCT00006252 Phase 2 fludarabine phosphate;Cyclophosphamide;G-CSF
24 Consolidation With Campath-1H After FMC Induction in Patients With T-cell Chronic Lymphocytic Leukemia Completed NCT00278213 Phase 2 cyclophosphamide;fludarabine phosphate;mitoxantrone hydrochloride
25 Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
26 Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
27 Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen Completed NCT00005804 Phase 2 cyclophosphamide
28 A Phase I-II Intensive-Dose Ifosfamide, Carboplatin and Taxotere (IC-T) Combination Chemotherapy Followed by Autologous Stem Cell Rescue for Patients With Refractory Malignancies Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
29 Phase II Study of High Dose Cyclophosphamide and Rituximab in Low Grade and Mantle Cell Lymphoma Completed NCT00278161 Phase 2 Cyclophosphamide
30 Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy Completed NCT00255749 Phase 2
31 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
32 Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation Completed NCT00053196 Phase 2 busulfan;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus;allopurinol
33 Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) in Newly Diagnosed and Relapsed Indolent Lymphoproliferative Malignancies Completed NCT00005626 Phase 2 Irinotecan
34 RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
35 A Phase I/II Study of Clofarabine in Patients With Relapsed T-Cell and NK-Cell Lymphomas Completed NCT00416351 Phase 1, Phase 2 clofarabine
36 Phase II Multicenter Trial Of Pentostatin and Rituximab In Patients With Previously Treated and Untreated Low Grade B-Cell Non-Hodgkin's Lymphoma (NHL) Including Chronic Lymphocytic Leukemia (CLL) Completed NCT00026351 Phase 2 pentostatin
37 Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Undergoing Dose-Adjusted Treatment With A Maximally Intensive Busulfex-Based Therapeutic Regimen Completed NCT00448357 Phase 1, Phase 2 busulfan;fludarabine phosphate;tacrolimus;methotrexate
38 Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment With a More Intensive Therapeutic Regimen Completed NCT00448201 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
39 OUTPATIENT SUBCUTANEOUS IL-2 AND ALPHA INTERFERON IN THE MANAGEMENT OF METASTATIC CANCER Completed NCT00002504 Phase 2
40 A Phase II Trial of Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies Completed NCT00782379 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
41 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
42 Allogeneic Hematopoietic Stem Cell Transplantation With Nonmyeloablative Conditioning for Patients With Chronic Lymphocytic Leukemia - A Multi-center Trial Completed NCT00060424 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
43 Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Completed NCT01008462 Phase 2 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
44 Phase II Trial of Combined Immunochemotherapy With Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients With Previously Treated or Untreated T-Prolymphocytic Leukemia Completed NCT01186640 Phase 2 Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab;Alemtuzumab
45 A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Nonmyeloablative Allogeneic Stem Cell Transplantation for Patients With Relapsed or Refractory Lymphoma - A Multi-center Trial Completed NCT00005803 Phase 1, Phase 2 Carmustine;Cyclophosphamide;Cyclosporine;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil
46 A Multicenter, Open-label, Single Arm Study of Weekly Alvocidib in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) Arising From CLL Completed NCT00464633 Phase 2 alvocidib
47 A Phase II Study to Assess Immunosuppression With Sirolimus Combined With Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD After Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation- A Multi-Center Trial Completed NCT01251575 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
48 Clinical Study of CD19/CD20 tanCAR T Cells in Relapsed and/or Chemotherapy Refractory B-cell Leukemias and Lymphomas Completed NCT03097770 Phase 1, Phase 2
49 Transplantation of Unrelated Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen Completed NCT00309842 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
50 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil

Search NIH Clinical Center for Prolymphocytic Leukemia

Cochrane evidence based reviews: leukemia, prolymphocytic

Genetic Tests for Prolymphocytic Leukemia

Anatomical Context for Prolymphocytic Leukemia

MalaCards organs/tissues related to Prolymphocytic Leukemia:

40
T Cells, Bone, Bone Marrow, Myeloid, B Cells, Liver, Skin

Publications for Prolymphocytic Leukemia

Articles related to Prolymphocytic Leukemia:

(show top 50) (show all 857)
# Title Authors PMID Year
1
[CD5-positive B-cell prolymphocytic leukemia]. 54 61
20134145 2010
2
Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy. 54 61
19278963 2009
3
Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia. 54 61
18073348 2008
4
High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. 54 61
17890451 2008
5
IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). 54 61
16642047 2006
6
D cyclins in CD5+ B-cell lymphoproliferative disorders: cyclin D1 and cyclin D2 identify diagnostic groups and cyclin D1 correlates with ZAP-70 expression in chronic lymphocytic leukemia. 61 54
16393687 2006
7
Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1. 61 54
15459205 2004
8
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. 61 54
15133473 2004
9
ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma. 54 61
12149228 2002
10
Breakpoints in the ataxia telangiectasia gene arise at the RGYW somatic hypermutation motif. 61 54
11821961 2002
11
Structure of murine Tcl1 at 2.5 A resolution and implications for the TCL oncogene family. 54 61
11679718 2001
12
TCL1 is activated by chromosomal rearrangement or by hypomethylation. 61 54
11241786 2001
13
Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. 54 61
10786666 2000
14
Aberrant splicing of the ATM gene associated with shortening of the intronic mononucleotide tract in human colon tumor cell lines: a novel mutation target of microsatellite instability. 54 61
10738255 2000
15
Role of TCL1 and ALL1 in human leukemias and development. 54 61
10197596 1999
16
Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia. 61 54
9657733 1998
17
Ataxia-telangiectasia and T-cell leukemias: no evidence for somatic ATM mutation in sporadic T-ALL or for hypermethylation of the ATM-NPAT/E14 bidirectional promoter in T-PLL. 61 54
9622061 1998
18
Inactivation of the ATM gene in T-cell prolymphocytic leukemias. 54 61
9573030 1998
19
Solution structure of the recombinant human oncoprotein p13MTCP1. 54 61
9691281 1998
20
Crystal structure of p14TCL1, an oncogene product involved in T-cell prolymphocytic leukemia, reveals a novel beta-barrel topology. 54 61
9519406 1998
21
Alternative origin of p13MTCP1-encoding transcripts in mature T-cell proliferations with t(X;14) translocations. 61 54
9315101 1997
22
Perforin-positive leukemic cell infiltration in the aortic tissue of a patient with T-cell prolymphocytic leukemia. 61 54
8971584 1996
23
Expression of p13MTCP1 is restricted to mature T-cell proliferations with t(X;14) translocations. 54 61
8634440 1996
24
Overexpression of the PRAD1 oncogene in a patient with prolymphocytic leukemia with t(11;14)(q13;q32). 61 54
7497446 1995
25
B-cell prolymphocytic leukemia expressing CD13 antigen. 61 54
7524729 1994
26
Burkitt-like mutations in the c-myc gene locus in prolymphocytic leukemia. 54 61
8182948 1994
27
Cyclin D1 overexpression in non-Hodgkin's lymphoma with chromosome 11 bcl-1 rearrangement. 54 61
8172823 1994
28
Induction of apoptosis in CD4+ prolymphocytic leukemia by deoxyadenosine and 2'-deoxycoformycin. 54 61
1528066 1992
29
Expression of the mdr3 gene in prolymphocytic leukemia: association with cyclosporin-A-induced increase in drug accumulation. 61 54
2323839 1990
30
Purine metabolism enzymes and immunological phenotype in chronic B-cell malignancies: chronic lymphocytic leukemia, prolymphocytic leukemia and hairy cell leukemia. 61 54
2125699 1990
31
Ibrutinib-induced acute kidney injury via interstitial nephritis. 61
33567947 2021
32
Shikonin Derivatives from Onsoma visianii Decrease Expression of Phosphorylated STAT3 in Leukemia Cells and Exert Antitumor Activity. 61
33807148 2021
33
Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. 61
33654067 2021
34
T-Cell Prolymphocytic Leukemia: An Overview of Current and Future Approaches. 61
33728186 2021
35
Cutaneous Presentation of T-Cell Prolymphocytic Leukemia Mimicking Dermatomyositis. 61
33606377 2021
36
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia 61
33626863 2021
37
The miR-200c/141-ZEB2-TGFβ axis is aberrant in human T-cell prolymphocytic leukemia. 61
33596640 2021
38
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. 61
33598678 2021
39
T-cell prolymphocytic leukemia: Insidious onset followed by aggressive course with cutaneous involvement. 61
33599388 2021
40
T-cell Prolymphocytic Leukemia, Cerebriform Variant. 61
33732560 2021
41
Optic nerve biopsy in leukemic infiltrative optic neuropathy: a case report and review of the literature. 61
33557696 2021
42
Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia. 61
32259827 2021
43
What to Look Out for when Transplanting T-Cell Prolymphocytic Leukemia. 61
32369824 2021
44
A Complex Karyotype in a 68-Year-Old Patient With T-PLL. 61
33684910 2021
45
T-Cell Prolymphocytic Leukemia: Long-Term Remissions Challenging! 61
32392564 2021
46
An Unusual Case of Prolymphocytic Leukemia Transformation in a Patient With Chronic Lymphocytic Leukemia. 61
33533282 2021
47
Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia. 61
32875608 2020
48
Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma. 61
32970500 2020
49
Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling. 61
33301031 2020
50
Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways. 61
33543866 2020

Variations for Prolymphocytic Leukemia

Expression for Prolymphocytic Leukemia

Search GEO for disease gene expression data for Prolymphocytic Leukemia.

Pathways for Prolymphocytic Leukemia

Pathways related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.19 TP53 MYC JAK3 JAK1 FCER2 CR2
2
Show member pathways
12.83 TP53 MYC JAK1 CCND1 ABL1
3 12.81 TP53 MYC JAK3 JAK1 CCND1 ABL1
4
Show member pathways
12.75 TP53 TCL1A MYC MTCP1 JAK3 JAK1
5
Show member pathways
12.68 TP53 MYC JAK3 JAK1 FCER2 CR2
6
Show member pathways
12.6 TP53 MYC JAK1 CCND1 ABL1
7 12.54 ZAP70 JAK3 JAK1 CD38 CD19
8 12.51 TP53 MYC CCND1 ATM ABL1
9
Show member pathways
12.45 ZAP70 MYC JAK1 CCND1
10
Show member pathways
12.38 MYC JAK3 JAK1 CCND1
11
Show member pathways
12.37 TP53 MYC CCND1 ATM ABL1
12 12.35 TP53 MYC CCND1 ATM ABL1
13
Show member pathways
12.32 TP53 MYC JAK3 JAK1 FCER2 CCND1
14 12.27 TP53 JAK3 JAK1 CCND1
15 12.25 TP53 MYC JAK3 JAK1 CCND1 ATM
16
Show member pathways
12.24 TP53 MYC JAK1 ATM ABL1
17
Show member pathways
12.22 TP53 CCND1 ATM ABL1
18 12.17 TP53 MYC JAK1 CCND1
19 12.13 TP53 MYC CCND1 ATM
20 11.99 TP53 MYC JAK1 CCND1 ATM ABL1
21 11.95 TP53 MYC CCND1 ATM ABL1
22 11.83 TP53 MYC CCND1
23 11.82 TP53 MYC CCND1 ABL1
24
Show member pathways
11.8 TP53 ATM ABL1
25 11.74 MYC CCND1 ADA
26 11.71 TP53 MYC CCND1
27 11.69 MYC CCND1 ATM ABL1
28
Show member pathways
11.67 MYC JAK3 JAK1
29 11.66 TP53 MYC ATM
30 11.63 JAK3 JAK1 FCER2
31 11.6 TP53 ATM ABL1
32 11.57 TP53 MYC JAK1 CCND1
33 11.5 TP53 MYC JAK1 ATM
34 11.49 TP53 MYC JAK3 JAK1 FCER2 CCND1
35
Show member pathways
11.47 MYC JAK3 JAK1 CCND1
36 11.45 TP53 MYC CCND1 ATM
37 11.36 ZAP70 JAK3 CD19 ADA
38 11.34 MYC JAK1 CCND1
39 11.29 TP53 CCND1 ATM
40 11.25 TP53 MYC CCND1 ATM ABL1
41
Show member pathways
11.18 MYC JAK3 JAK1
42 11.1 TP53 MYC ABL1
43 11.1 FCER2 CR2 CD7 CD5 CD38 CD19
44
Show member pathways
11.05 TP53 MYC ATM ABL1

GO Terms for Prolymphocytic Leukemia

Cellular components related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 9.86 ZAP70 TP53 MYC JAK3 JAK1 FCER2
2 protein-containing complex GO:0032991 9.1 TP53 TCL1A MYC MTCP1 CD19 ABL1

Biological processes related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.02 ZAP70 JAK3 CR2 CD7 CD19 ATM
2 negative regulation of apoptotic process GO:0043066 10 TP53 TCL1A MYC CD38 ADA
3 cellular response to DNA damage stimulus GO:0006974 9.97 TP53 MYC CCND1 ATM ABL1
4 regulation of apoptotic process GO:0042981 9.88 TP53 JAK3 ATM ABL1
5 protein phosphorylation GO:0006468 9.8 ZAP70 JAK3 JAK1 CCND1 ATM ABL1
6 regulation of cell cycle GO:0051726 9.67 TP53 CCND1 ATM ABL1
7 positive regulation of response to DNA damage stimulus GO:2001022 9.61 MYC ATM
8 regulation of cellular senescence GO:2000772 9.6 TP53 ABL1
9 interleukin-15-mediated signaling pathway GO:0035723 9.59 JAK3 JAK1
10 T cell activation GO:0042110 9.58 ZAP70 CD7 ADA
11 interleukin-2-mediated signaling pathway GO:0038110 9.57 JAK3 JAK1
12 positive regulation of alpha-beta T cell differentiation GO:0046638 9.56 ZAP70 ADA
13 peptidyl-tyrosine phosphorylation GO:0018108 9.56 ZAP70 JAK3 JAK1 ABL1
14 interleukin-9-mediated signaling pathway GO:0038113 9.54 JAK3 JAK1
15 response to vitamin E GO:0033197 9.52 CCND1 ADA
16 mitotic G1 DNA damage checkpoint GO:0031571 9.51 TP53 CCND1
17 negative regulation of thymocyte apoptotic process GO:0070244 9.49 JAK3 ADA
18 interleukin-21-mediated signaling pathway GO:0038114 9.48 JAK3 JAK1
19 DNA damage induced protein phosphorylation GO:0006975 9.46 ATM ABL1
20 cell cycle arrest GO:0007050 9.46 TP53 MYC ATM ABL1
21 B cell proliferation involved in immune response GO:0002322 9.43 CD19 ABL1
22 response to drug GO:0042493 9.35 TP53 MYC CD38 CCND1 ADA
23 cytokine-mediated signaling pathway GO:0019221 9.1 TP53 MYC JAK3 JAK1 FCER2 CCND1

Molecular functions related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.73 ZAP70 JAK3 JAK1 CCND1 ATM ABL1
2 protein phosphatase binding GO:0019903 9.5 TP53 JAK3 JAK1
3 protein tyrosine kinase activity GO:0004713 9.46 ZAP70 JAK3 JAK1 ABL1
4 protein kinase activity GO:0004672 9.43 ZAP70 JAK3 JAK1 CCND1 ATM ABL1
5 non-membrane spanning protein tyrosine kinase activity GO:0004715 8.92 ZAP70 JAK3 JAK1 ABL1

Sources for Prolymphocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....